Eribulin Monomethanesulfonate
Urinary Bladder Carcinoma
Explore 121 assets in Urinary Bladder Carcinoma →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Eisai Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01126749CT.gov Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer | — | Terminated | — | — | — |
NCT00365157CT.gov Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eribulin Monomethanesulfonate (this asset) | Eisai Inc. | P1/2 | CC · 43 |
| Cis-Diamminedichloroplatinum Ii | G1 Therapeutics, Inc. | P3 | BBB |
| Trastuzumab | NKGen Biotech, Inc. | P2 | BB |
| Carboplatin | G1 Therapeutics, Inc. | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Vinblastine | University of Southern California | P3 | BB |
| Pembrolizumab | Essen Biotech | P3 | BB |
| Adriamycin | Toray Industries, Inc | P3 | BB |
| Nivolumab | National Cancer Institute (NCI) | P2/3 | BB |
+42 more in the Urinary Bladder Carcinoma cohort
Other indications for Eribulin Monomethanesulfonate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P4 | BB · 69 |
| Breast Cancer | — | P4 | BB · 69 |
| Toxic Encephalopathy | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eribulin Monomethanesulfonate in Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eribulin-monomethanesulfonate-urinary-bladder-carcinoma-64775
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →